SARS-CoV-2 has caused tens of thousands of infections and more than one thousand deaths. There are currently no registered therapies for treating coronavirus infections. Because of time consuming process of new drug development, drug repositioning may be the only solution to the epidemic of sudden infectious diseases. We systematically analyzed all the proteins encoded by…
Acta Pharmaceutica Sinica B Template
Write in a clean editor, then format for Acta Pharmaceutica Sinica B in one click — DocuGuru applies the official Elsevier template with numbered references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
About the Acta Pharmaceutica Sinica B format
Acta Pharmaceutica Sinica B is a peer-reviewed journal published by Elsevier, covering Nanoplatforms for cancer theranostics, Nanoparticle-Based Drug Delivery, RNA Interference and Gene Delivery.
| Publisher | Elsevier |
|---|---|
| Reference style | Numbered (Elsevier) Numbered — [1], [2] in the text [1] A. Smith, B. Jones, C. Lee, A representative article title, Acta Pharmaceutica Sinica B 12 (2023) 45–58.
Formats any DOI in Acta Pharmaceutica Sinica B style. No sign-up. |
| Publishes research in | Nanoplatforms for cancer theranostics Nanoparticle-Based Drug Delivery RNA Interference and Gene Delivery Diverse Scientific and Economic Studies Immunotherapy and Immune Responses |
| ISSN | 2211-3835 |
| Citation impact (2-yr) | 8.96 |
| h-index | 166 |
| i10-index | 1,934 |
| Total citations | 141,264 |
| Open access | Yes |
| Top institutions publishing here | Chinese Academy of Medical Sciences & Peking Union Medical College |
| Journal website | www.journals.elsevier.com |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Papers published in Acta Pharmaceutica Sinica B per year
Citation impact of Acta Pharmaceutica Sinica B by publication year
Citations each year’s papers have accumulated so far — the most recent years are still building up.
Most-cited papers in Acta Pharmaceutica Sinica B
Hypoxia-inducible factor-1 (HIF-1) has been recognized as an important cancer drug target. Many recent studies have provided convincing evidences of strong correlation between elevated levels of HIF-1 and tumor metastasis, angiogenesis, poor patient prognosis as well as tumor resistance therapy. It was found that hypoxia (low O2 levels) is a common character in many types…
Ninety percent of clinical drug development fails despite implementation of many successful strategies, which raised the question whether certain aspects in target validation and drug optimization are overlooked? Current drug optimization overly emphasizes potency/specificity using structure‒activity-relationship (SAR) but overlooks tissue exposure/selectivity in disease/normal tissues using structure‒tissue exposure/selectivity-relationship (STR), which may mislead the drug candidate selection…
The emerging trends in the combinatorial chemistry and drug design have led to the development of drug candidates with greater lipophilicity, high molecular weight and poor water solubility. Majority of the failures in new drug development have been attributed to poor water solubility of the drug. Issues associated with poor solubility can lead to low…
Exosomes are small intracellular membrane-based vesicles with different compositions that are involved in several biological and pathological processes. The exploitation of exosomes as drug delivery vehicles offers important advantages compared to other nanoparticulate drug delivery systems such as liposomes and polymeric nanoparticles; exosomes are non-immunogenic in nature due to similar composition as body׳s own cells.…